Structure and activity of plasmin and other direct thrombolytic agents.
The physiological or pharmacological dissolution of thrombi is ultimately accomplished by the serine protease plasmin. Plasmin is derived from its precursor plasminogen in a reaction catalyzed by plasminogen activators (PAs) such as tissue-type plasminogen activator (tPA). In the middle of the last century, plasmin was investigated as a potential thrombolytic agent. However, technical obstacles led to the abandonment of this agent, and by the 1970s PAs had become the standard of care for pharmacological management of various thrombotic conditions. Talecris Biotherapeutics has developed a methodology to prepare the plasmin product (Human) TAL-05-00018 that is rendered inactive by low pH (pH 3.0-4.0) until it is delivered directly to the neutral environment of a thrombus by catheter-assisted administration. TAL-05-00018 undergoes a rigorous manufacturing process to ensure a final product free from unactivated plasminogen, streptokinase, enveloped and non-enveloped viruses and prion proteins; generating an extremely high-purity product with a shelf life of three years at ambient temperature. TAL-05-00018 has shown promise in in vitro and pre-clinical studies, and in early clinical trials, demonstrating a dose-dependant reduction in clot weight that compares favorably to that seen with tPA. Several other direct thrombolytics have also been developed, including the recombinant, modified deletion mutant of plasmin TAL6003 (Talecris Biotherapeutics), which retains all the major functional attributes of full-length plasmin.
Novokhatny
Valery
V
Talecris Biotherapeutics, RTP, USA. valery.novokhatny@talecris.com
D005341:Fibrinolysin / Q000737:chemistry* / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D005341:Fibrinolysin